人類靜脈注射免疫球蛋白
人類靜脈注射免疫球蛋白 (hIVIG) 是一種純化的血液製品，用於治療犬隻嚴重的免疫介導疾病。**臨床提示：** 其在免疫介導性血小板減少症 (IMT) 的療效與長春新鹼 (vincristine) 相當，但在免疫介導性溶血性貧血 (IMHA) 的使用仍具爭議。> **警告：** 應保留用於其他治療失敗的特殊病例。
作用機制: The drug has both immediate and long-term immunomodulatory effects, though exact mechanisms are not fully elucidated. * **Immediate effects:** Binding to **Fc receptors** on macrophages (preventing phagocytosis of opsonized cells) and providing **anti-idiotype antibodies**. * **Long-term effects:** Reacts with membrane receptors on **T cells**, **B cells**, and **monocytes** → alters immune system autoregulation, reduces autoreactivity, and induces tolerance to self.
各物種劑量
- Severe immune-mediated diseases (e.g., IMT, acute polyradiculoneuritis) · 0.5-1.0 g/kg (Higher doses of up to 2.2 g/kg are used in some studies) · IV · Administered over 6-8 hours · Single infusion · Administer slowly over 6-8 hours.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新藥品仿單及個別病患確認。
給藥途徑
禁忌症
- Patients with increased plasma protein levels (hyperproteinaemia)
不良反應
- Anaphylactic reactions (theoretical risk, though not widely recorded in dogs)
藥物相互作用
- Highly protein-bound drugs · Use with care due to potential binding displacement or alterations in plasma protein dynamics · moderate
- Vaccines · May interfere with the immune response to vaccination; use with care · moderate
監測
- Plasma protein levels
- Signs of anaphylaxis during infusion
- Clinical signs of immune-mediated disease resolution (e.g., platelet counts)
過量
No specific overdose information is provided in the monograph. However, excessive administration may lead to severe hyperproteinaemia, hyperviscosity syndrome, and volume overload.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。